|
Symposium
Immunogenicity of Biologic Therapeutics
Speakers:
Soumi Gupta, Anu Cherukuri, Lynne Jesaitis, Andrew Melton, Kevin Larimore, Brian Long (Biomarin); Shan Chung, Valerie Quamby, Montserrat Carrasco-Triguero, Eric Wakshull (Genentech)
Organizers:
Date:
2017-10-11
Time:
8:45-17:00 Pacific Time
Registration fee:
(USD): Regular: $195; Academic: $125; Students & Unemployed: $35
Location:
Crowne Plaza, Foster City, CA
Major Sponsor:
Vendor show vendors registered to date:
(14)AIT Bioscience; AIT Bioscience; Aragen Bioscience, Inc.; Eurofins; Immudex; Intertek; inVentiv Health Clinical; JOINN Labs; MicroConstants; Pacific BioLabs; PPD; Precision for Medicine; Science Exchange; WuXi AppTec
Registration: http://www.PBSS.org
Registration deadline:2017-10-10
(it will close sooner if the seating cap is reached)
About the Topic
Biotechnology-derived (biologics) therapeutics including monoclonal antibodies, proteins, peptides, and enzymes have provided patients with targeted and effective medicines for numerous diseases. All therapeutic proteins have the potential to generate immune responses or immunogenicity through the anti-drug antibody (ADA) formation or cell based immune responses. The challenge for industry is to understand the factors contributing to and predicting immunogenicity, to design assays to measure and monitor the immune response, and find improved methods of administering the biologic therapeutics to minimize any negative impact.
This symposium will discuss challenges imposed by new FDA guidances and bioanalytical strategies for measuring clinical immunogenicity, tools for immunogenicity prediction, strategies for minimizing immunogenicity in the clinic and integrated data analysis plans.
Agenda:
8:45 – 10:15 am: Overview of immunogenicity of Biologic Therapeutics (Soumi Gupta, Anu Cherukuri)
10:20 – 10:50 am: Strategies for Bioanalytical Analysis to Enable Clinical Immunogenicity Assessment and Addressing new FDA Immunogenicity Assay Guidance – Challenges and Approaches (Andrew Melton)
10:55 – 11:10 am: Break
11:10 – 11:20 am: Major Sponsor's presentation (Medpace)
11:30 am – 12: 00 pm: Tools for immunogenicity prediction (Shan Chung)
12:00 – 1:00 pm: Lunch
1:05 – 1:35 pm: Risk-Based Approach for Assessment of Impurities (Valerie Quamby)
1:40 – 2:10 pm: Fit for Purpose NAb Assay Development (Kevin Larimore)
2:10 – 2:40 pm: Immune Tolerance (Brian Long)
2:40 - 2:55 pm: Break
3:00 – 3:30 pm: Immunogenicity of ADC and multi-domain characterization (Montserrat Carrasco-Triguero)
3:40 – 4:10 pm: Integrated Clinical Data Analysis (Eric Wakshull)
4:10 – 4:30 pm: Panel Discussion
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
|
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
|
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
|
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)
|
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
|
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
|
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
|
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
|
Ads (in random order)
Submit a Text Ad
($250 for 2 months)
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Lena Biosciences
Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
|
Hypha Discovery
Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
|
Lena Biosciences
Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
|
Submit a Text Ad
|